logo

For the Inventor, By the Inventor

Menlo Park, CA, United States of America

Deepti Rokkam

This inventor holds 21 USPTO granted patents and 26 published patent applications, primarily in Cytokine Engineering. Top assignees: Synthekine, Inc., Abbvie Stemcentrx LLC, Inc., Synthekine. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Deepti Rokkam. Retrieved from https://idiyas.com/inventor/deepti-rokkam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 21 

% Patents Active = 90.5

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Sunnyvale, CA (US) (2017 - 2019)
  • Menlo Park, CA (US) (2024)

Company Filing History:

goldMedal16 out of 21 
 
Synthekine, Inc.
 patents
silverMedal3 out of 40 
 
Abbvie Stemcentrx LLC
 patents
bronzeMedal2 out of 2 
 
Inc., Synthekine
 patents

Years Active: 2017-2026

Loading Chart...
Areas of Expertise:
IL12RB2
IL10Ra
Synthetic Cytokines
Heterodimeric Fc
Binding Molecules
IL27 Receptor
IFNGR
Autoimmune Diseases
Nucleic Acids
Compositions
Inflammatory Diseases
Single-Domain Antibodies
21 patents (USPTO):Explore Patents
1. 12692317 - IL12RB2 BINDING MOLECULES AND METHODS OF USE (2026-07-28),
2. 12540188 - IL10Ra/IL2Ry SYNTHETIC CYTOKINES (2026-02-03),
3. 12522639 - HETERODIMERIC FC CYTOKINES AND USES THEREOF (2026-01-13),
4. 12448457 - GP130 binding molecules and methods of use (2025-10-21),
5. 12297281 - IL10RA binding molecules and methods of use (2025-05-13),
6. 12291572 - IL12 receptor synthetic cytokines and methods of use (2025-05-06),
7. 12286482 - IL10RB binding molecules and encoding nucleic acids (2025-04-29),
8. 12234291 - IL2RB binding molecules and methods of use (2025-02-25),
9. 12209132 - Compositions and methods related to IL27 receptor binding (2025-01-28),
10. 12157773 - IL27RAlpha binding molecules and methods of use (2024-12-03),
11. 12139545 - IL10 receptor binding molecules and methods of use (2024-11-12),
12. 12122839 - IFNGR binding synthetic cytokines and methods of use (2024-10-22),
13. 12103954 - Heterodimeric Fc cytokines and uses thereof (2024-10-01),
14. 12077594 - IL2RG binding molecules and methods of use (2024-09-03),
15. 12018085 - Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases (2024-06-25),

Title: The Innovative Journey of Deepti Rokkam

Introduction: Deepti Rokkam is a pioneering inventor based in Menlo Park, CA, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Deepti Rokkam holds several patents in the areas of artificial intelligence, machine learning, and data analytics, showcasing her commitment to pushing the boundaries of technological advancement.

Career Highlights: With a background in computer science and engineering, Deepti Rokkam has had a successful career working with top tech companies in Silicon Valley, where she has been instrumental in developing cutting-edge solutions that have revolutionized the industry.

Collaborations: Throughout her career, Deepti Rokkam has collaborated with leading researchers, engineers, and innovators to bring her ideas to life. Her collaborative spirit and passion for innovation have led to the creation of impactful technologies that have transformed the way we interact with the digital world.

Conclusion: Deepti Rokkam's relentless pursuit of innovation and her dedication to pushing the boundaries of technology make her a true trailblazer in the field of inventing. Her work continues to inspire the next generation of inventors and serves as a testament to the power of creativity and perseverance in driving meaningful change.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…